This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

John Richards, Ph.D.
Global Drug Development/Technical Research & Development at Novartis

Profile

John Richards is  currently working at Novartis in the Technical Research and Development Group  subsequent their acquisition of The Medicines Company where he was Senior Vice President of Pharmaceutical Development having  lead CMC drug development activities since the company’s inception and is an expert in the scale up and manufacture of complex Peptide and Oligonucleotide based molecules.

John who is English by birth read Chemistry for his Bachelors at St John’s College Oxford prior to completing a DPhil in Peptide Chemistry also at Oxford. Following his doctorate John carried out post doctoral research in the Laboratory of Dr RC Sheppard at the MRC Laboratory of Molecular Biology in Cambridge, working as a part of the team which developed the now almost universally utilized Fmoc-solid phase synthesis methodology.  Subsequent to further research as a staff scientist into Neuro transmitter peptides in the MRC Neurochemical Pharmacology Unit also in Cambridge John moved into industry, initially as a part a start up company formed by alumni of The Laboratory of Molecular Biology .

Subsequently after his start up was acquired John continued working at ICI Pharmaceuticals (Astra Zeneca) on the development of peptides as commercial pharmaceutical intermediates. He moved with his family to the United States in 1993 working initially in biotechnology before joining The Medicines Company in 1997.  One of his major accomplishments at The Medicines Company was leading the scale up and commensurate cost reductions for a Peptide drug bivalirudin ultimately enabling ton quantities to be manufactured at low cost.

Agenda Sessions

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A - Control of Impurities and Overall Purity in GalNAc siRNA Conjugates

    14:45